Figure 1.
Decision tree structure.
Table 1.
Pharmaceutical costs and other model parameters.
Figure 2.
Flow diagram of literature search.
Figure 3.
Evidence structure and estimated odds ratios.
Figures above the diagonal show the number of studies with corresponding comparison. Figures below the diagonal show the odds ratio (left vs top), mean and 95% credibility intervals. Grey boxes indicate if direct comparisons were available; white boxes indicate odds ratios are based only on indirect comparison. Numbers in bold indicate at least 95% probability that estimate is different from 1.
Table 2.
Odds ratios on remission using standard DerSimonian and Laird random-effects pair-wise meta-analysis and Bayesian MTC.
Table 3.
Estimated probability of remission in different scenarios.
Table 4.
Results cost-effectiveness analysis with societal perspective.
Table 5.
Results cost-effectiveness analysis with health-care perspective.
Figure 4.
Cost-effectiveness acceptability curves.
Note: All treatments except escitalopram, mirtazapine, venlafaxine and duloxetine have a low probability of being cost effective at all willingness-to-pay values of a health outcome, hence the curves for these treatments virtually lie on the abscissa.